Dermatology · Mycosis Fungoides

Diagnosis and Pathology: Decoding Your Report

At a Glance

Mycosis fungoides is diagnosed by combining the skin exam and biopsy findings with immune-marker and sometimes T-cell receptor testing; no single term, stain, or genetic result proves the diagnosis, and variants can affect treatment and outlook.

A diagnosis of Mycosis Fungoides (MF) is rarely made with a single test. Instead, it is a puzzle that doctors piece together using your clinical history, the physical appearance of your skin, and detailed microscopic analysis of your tissue ^[1]^[2]. Because early MF looks so much like common skin conditions such as eczema or psoriasis, the pathology report is the most critical tool for distinguishing cancer from a simple rash.

The Language of Your Pathology Report

When a pathologist looks at your skin sample, they search for specific “clues” that T-cells (a type of white blood cell) have become cancerous. You may see these terms on your report. However, it is important to understand that these findings can support the diagnosis but are not individually diagnostic; some can occur in inflammatory skin disease:

Epidermotropism: This is a hallmark of MF. It means that atypical T-cells are migrating into the epidermis (the top layer of skin) without the typical swelling or fluid usually seen in an inflammatory rash ^[1]^[3]. What it does not prove: Benign rashes can also show cells moving into the epidermis.
Pautrier Microabscesses: These are small clusters of atypical T-cells found within the epidermis. While they are highly suggestive of MF, they are only found in about 25–35% of cases ^[1].
Cerebriform Nuclei: This describes T-cells with “brain-like,” folded nuclei. Seeing these cells under the microscope is a strong indicator of a cutaneous T-cell lymphoma ^[4]. What it does not prove: Mildly folded nuclei can appear in reactive conditions.

Immunophenotyping: The “ID Tags” of Your Cells

Pathologists use stains to identify proteins on the surface of your cells, known as markers.

CD4+ and CD8-: Most MF cases involve CD4 “helper” T-cells. A normal rash usually has a mix of CD4 and CD8 cells. In MF, the ratio is often skewed, with far more CD4 cells than CD8 cells, though CD8-positive MF also occurs ^[5]^[6].
CD7 Loss: Healthy T-cells almost always carry the CD7 marker. One of the common signs of a cancerous T-cell in MF is that it “drops” or loses this marker. CD7 loss is found in about 72% of early-stage MF cases ^[7]^[8]. What it does not prove: Some benign inflammatory conditions also feature CD7 loss.
CD30: This marker is often checked on the cells ^[9]. Crucial Note: CD30 positivity alone does not mean the disease has undergone large-cell transformation.

TCR Gene Rearrangement: The “DNA Fingerprint”

You might see a section on TCR gene rearrangement or clonality. A T-cell receptor (TCR) test looks for patterns. If a biopsy shows a dominant pattern of T-cell receptors (meaning they are clonal), it suggests many cells came from one original cancerous cell ^[10].

Crucial Note: A clonal result is not a standalone diagnosis. Some benign skin conditions can show clonality, and some early MF cases may not show it yet ^[11]^[12]. Your doctor must interpret this result alongside your physical symptoms.

Exploring the Variants

MF can present in several “variants” that change how the disease looks and how it is treated:

Folliculotropic MF (FMF): The atypical cells surround hair follicles. This variant can cause hair loss (alopecia) or acne-like bumps. Because the cells are deeper in the skin, it may require more intensive light therapy or different treatments ^[13]^[14].
Pagetoid Reticulosis: Usually appears as a single, slow-growing, scaly patch, often on the hands or feet. It is very slow-moving and has an excellent outlook, with many patients achieving complete remission ^[15]^[16].
Syringotropic MF: A rare version where the cells invade the sweat glands (eccrine glands). It often follows a mild course and is sometimes found alongside the folliculotropic variant ^[17]^[18].
Granulomatous Slack Skin (GSS): An extremely rare variant that causes the skin to become loose or pendulous, typically in the armpits or groin. It involves a specific type of inflammation called “granulomatous” ^[19]^[20].
Erythrodermic MF: This involves nearly the entire body, causing widespread redness and scaling. It is an advanced form that requires careful blood testing to distinguish it from Sézary Syndrome, a related but more aggressive condition ^[21]^[22].

Completeness Checklist: Is Your Report Detailed Enough?

To ensure an accurate diagnosis, your pathology report should ideally include the following:

[ ] Site of Biopsy: Which lesion was sampled (e.g., “right thigh patch”).
[ ] Histology Description: Mention of epidermotropism or atypical cells ^[4].
[ ] Marker Panel: Results for CD3, CD4, CD8, and CD7 ^[8].
[ ] CD30 Status: Especially if larger cells are present ^[9].
[ ] Molecular Studies: TCR gene rearrangement results, if performed ^[23].
[ ] Clinical Correlation: A comment from the pathologist linking the microscopic findings to your physical symptoms ^[4].

Common questions in this guide

How is mycosis fungoides diagnosed?

There is no single test that diagnoses mycosis fungoides. Doctors combine your skin history and examination with one or more biopsies, microscopic findings, immune-marker tests, and sometimes T-cell receptor gene testing. Results must be interpreted together because several individual findings can also occur in inflammatory skin conditions.

What does epidermotropism mean on a mycosis fungoides biopsy report?

Epidermotropism means atypical T cells are present in the epidermis, the outermost layer of skin. It is an important clue that can support mycosis fungoides, but it does not prove the diagnosis because some inflammatory rashes can show a similar pattern.

What do CD7 loss and a high CD4-to-CD8 ratio mean?

CD7 loss and an unusually high proportion of CD4 cells compared with CD8 cells can support mycosis fungoides. Neither finding is diagnostic by itself, because benign inflammatory skin conditions can also show CD7 loss and mycosis fungoides can sometimes involve CD8 cells. Your pathologist interprets these results with the biopsy appearance and clinical findings.

Does a clonal T-cell receptor result confirm mycosis fungoides?

No. A clonal T-cell receptor result means many T cells share a similar receptor pattern, which can support the diagnosis. Benign skin conditions can also show clonality, and some early mycosis fungoides biopsies may not show it, so the result must be matched with the skin examination and biopsy findings.

What is folliculotropic mycosis fungoides?

Folliculotropic mycosis fungoides is a variant in which abnormal T cells surround hair follicles. It may cause hair loss or acne-like bumps, and because the cells are deeper in the skin, treatment may require a different or more deeply penetrating approach. Your care team can interpret whether this pattern appears in your biopsy.

Does CD30 positivity mean mycosis fungoides has transformed?

Not by itself. CD30 can be present on cells in mycosis fungoides, but CD30 positivity alone does not establish large-cell transformation. The pathologist considers the size and appearance of the cells and the clinical context when assessing transformation and its effect on outlook.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on mycosis fungoides variant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.How many biopsies were reviewed, and does my pathology report state that the findings are 'diagnostic of' or merely 'suggestive of' Mycosis Fungoides?
2.In my pathology report, is there evidence of CD7 loss or a CD4/CD8 ratio greater than 4? How do these findings support the diagnosis?
3.Does my biopsy show 'folliculotropism' or 'syringotropism,' and does that mean we need to consider deeper-penetrating treatments?
4.Was a T-cell receptor (TCR) gene rearrangement test done, and if so, how does the result fit with the physical appearance of my skin?
5.Does the pathology report mention 'large cell transformation' or CD30 expression? If so, what does that mean for my prognosis?

Key takeaways

Mycosis fungoides diagnosis requires the clinical history and skin examination to be interpreted alongside biopsy findings rather than relying on a single test.
Epidermotropism, Pautrier microabscesses, cerebriform nuclei, CD7 loss, a skewed CD4-to-CD8 ratio, and T-cell clonality can support but do not individually prove the diagnosis.
A clonal T-cell receptor result can support mycosis fungoides, but benign skin conditions may also show clonality and early disease may have a negative result.
Folliculotropic, pagetoid reticulosis, syringotropic, granulomatous slack skin, and erythrodermic variants have distinct patterns that may affect treatment or outlook.
A detailed report should identify the biopsy site, microscopic findings, marker results, CD30 status, molecular studies, and how the findings correlate with the skin examination.

References (23)

1
Practical Aspects Regarding the Histopathological Diagnosis of Early Mycosis Fungoides.
Tebeică T, Andrei R, Zurac S, Stăniceanu F
Romanian journal of internal medicine = Revue roumaine de medecine interne 2016; (54(1)):3-10 doi:10.1515/rjim-2016-0001.
PMID: 27141565
2
Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas.
Vandergriff T, Nezafati KA, Susa J, et al.
Journal of cutaneous pathology 2015; (42(5)):318-28 doi:10.1111/cup.12470.
PMID: 25721994
3
Mycosis fungoides with spongiosis: A potential diagnostic pitfall.
Shamim H, Johnson EF, Gibson LE, Comfere N
Journal of cutaneous pathology 2019; (46(9)):645-652 doi:10.1111/cup.13477.
PMID: 30989664
4
When mycosis fungoides seems not to be within the spectrum of clinical and histopathological differential diagnoses.
Di Prete M, Michelerio A, Lora V, et al.
Dermatology reports 2024; (16(Suppl 2)):10008 doi:10.4081/dr.2024.10008.
PMID: 39295886
5
CD8-positive Mycosis Fungoides Masquerading as Pyoderma Gangrenosum.
Saha M, Jain BB, Chattopadhyay S, Podder I
Indian journal of dermatology 2016; (61(5)):580 doi:10.4103/0019-5154.190126.
PMID: 27688458
6
Decoding Early Mycosis Fungoides: Histopathologic and Immunohistochemical Clues.
Kaya Terzi N
Cureus 2024; (16(4)):e57545 doi:10.7759/cureus.57545.
PMID: 38577165
7
Prognostic Value of Immunohistochemical T-Cell Marker Loss in Early-Stage Mycosis Fungoides: A Single-Center Cohort Study.
Jerkovic Gulin S, Ilic I, Gulin D, et al.
Dermatopathology (Basel, Switzerland) 2025; (12(3)) doi:10.3390/dermatopathology12030029.
PMID: 40981343
8
Erythrodermic CD4/CD8 Double-Negative Mycosis Fungoides: A Case Report.
Alnasser MA, AlKhawajah NM, AlQadri NG, et al.
Case reports in oncology 2021; (14(1)):256-261 doi:10.1159/000512822.
PMID: 33776713
9
Nodal Involvement by CD30+ Cutaneous Lymphoproliferative Disorders and Its Challenging Differentiation From Classical Hodgkin Lymphoma.
Lezama LS, Gratzinger D
Archives of pathology & laboratory medicine 2018; (142(1)):139-142 doi:10.5858/arpa.2016-0352-RS.
PMID: 29257929
10
Inflammatory and Infectious Cutaneous Entities Resembling Cutaneous T-Cell Lymphoma (CTCL): An Integrated Clinicopathological Review.
Nasser Eldin J, El Tayar E, Abbas O, Bhawan J
Dermatopathology (Basel, Switzerland) 2026; (13(2)) doi:10.3390/dermatopathology13020023.
PMID: 42346175
11
T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides.
Sufficool KE, Lockwood CM, Abel HJ, et al.
Journal of the American Academy of Dermatology 2015; (73(2)):228-36.e2.
PMID: 26048061
12
Relationship Between Pityriasis Lichenoides and Mycosis Fungoides: A Clinicopathological, Immunohistochemical, and Molecular Study.
Zaaroura H, Sahar D, Bick T, Bergman R
The American Journal of dermatopathology 2018; (40(6)):409-415 doi:10.1097/DAD.0000000000001057.
PMID: 29210716
13
Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides.
Kreutzer KM, Effendy I
Dermatology and therapy 2020; (10(5)):1175-1180 doi:10.1007/s13555-020-00429-0.
PMID: 32833161
14
Acneiform Presentations of Folliculotropic Mycosis Fungoides.
Shamim H, Riemer C, Weenig R, et al.
The American Journal of dermatopathology 2021; (43(2)):85-92 doi:10.1097/DAD.0000000000001698.
PMID: 33492839
15
Woringer-Kolopp disease (localized pagetoid reticulosis): a systematic review.
Osto M, Afify O, Musa A, et al.
International journal of dermatology 2023; (62(3)):312-321 doi:10.1111/ijd.16224.
PMID: 35485962
16
[Unusual course of CD8+ epidermotropic cutaneous T-cell lymphoma].
Gardette E, Moguelet P, Barete S, et al.
Annales de dermatologie et de venereologie 2016; (143(12)):846-851 doi:10.1016/j.annder.2016.03.022.
PMID: 27161647
17
Syringotropic Mycosis Fungoides: A Rare Form of Cutaneous T-cell Lymphoma Enabling a Histopathologic "Sigh of Relief".
Lehmer LM, Amber KT, de Feraudy SM
The American Journal of dermatopathology 2017; (39(12)):920-923 doi:10.1097/DAD.0000000000000926.
PMID: 28692463
18
Syringotropic Mycosis Fungoides: A Variant of Folliculotropic Mycosis Fungoides or a Distinct Entity?
Echols KF, Bressler L, Armeson K, Maize JC
The American Journal of dermatopathology 2019; (41(11)):807-809 doi:10.1097/DAD.0000000000001403.
PMID: 30946094
19
Granulomatous slack skin: a rare subtype of mycosis fungoides.
Motta LMD, Soares CT, Nakandakari S, et al.
Anais brasileiros de dermatologia 2017; (92(5)):694-697 doi:10.1590/abd1806-4841.20175099.
PMID: 29166509
20
Granulomatous slack skin T-cell lymphoma: an important differential diagnosis with giant cell tumor of soft tissue.
Adriano AR, Lima TS, Battistella M, Bagot M
Anais brasileiros de dermatologia 2015; (90(6)):892-5.
PMID: 26734874
21
Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.
Miyashiro D, Sanches JA
Frontiers in oncology 2023; (13()):1141108 doi:10.3389/fonc.2023.1141108.
PMID: 37124514
22
Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
Miyashiro D, Sanches JA
International journal of dermatology 2022; (61(4)):442-454 doi:10.1111/ijd.15865.
PMID: 34435672
23
Mycosis fungoides with epidermal mucinosis: a variant of mycosis fungoides with a spongiosis-like pattern.
Hu SW, Ratech H, Naeem R, et al.
Journal of cutaneous pathology 2015; (42(10)):730-8 doi:10.1111/cup.12513.
PMID: 26009972

This page explains Mycosis Fungoides biopsy and pathology terms for informational purposes only and does not constitute medical advice. Your treating clinician should interpret your report in the context of your skin findings and medical history.

Guide Contents